Summary
The plasma concentration-time curve of the hydrolysis product of bopindolol has been investigated in 14 patients with cirrhosis and in 15 healthy volunteers given a single oral dose of 2 mg bopindolol. Cirrhosis was confirmed by history and clinical examination or liver biopsy.
The time to maximum concentration, maximum concentration and AUC of hydrolyzed bopindolol were similar in the patients and controls. However, the elimination half-life was 6.0 h in controls and 9.5 h in cirrhotics. Antipyrine clearance was markedly decreased in patients with cirrhosis, but no correlation was found with the pharmacokinetic parameters of hydrolysed bopindolol.
Although the AUC was not significantly altered in patients with cirrhosis, the longer half-life of hydrolysed bopindolol suggests impairment of its disposition in liver disease, which could lead to significant accumulation of drug during chronic dosing.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aellig WH (1982) Clinical pharmacological experiments with bopindolol (LT-31–200): a long β-adrenoceptor blocking drug with partial agonistic activity. Br J Clin Pharmacol 13: 267–268 P
Aellig WH (1985) Pharmacological experiments in healthy volunteers with bopindolol, a long-acting β-adrenoceptor blocking drug with partial agonistic activity. Br J Clin Pharmacol 19: 775–781
Aellig WH, Nüersch E, Engel G, Grevel J, Niedburger W, Rosenthaler J (1986) Relationship between plasma concentrations and cardiac β-adrenoceptor blockade — a study with oral and intravenous bopindolol. Br J Clin Pharmacol 21: 45–51
Andreasen PB, Ranek L, Statland BE, Tygstrup N (1974) Clearance of antipyrine dependence of quantitative liver function. Eur J Clin Invest 4: 129–134
Berthold R, Waite R, Weber H (1981) Pharmacological studies with bopindolol: a new long acting β-adrenoceptor antagonist. Br J Pharmacol 74: 829P
Branch RA (1982) Drugs as indicators of hepatic function. Hepatology 2: 97–105
Eichelbaum M, Somogyi A (1977) Rapid and sensitive method for the determination of antipyrine in biological fluids by high liquid chromatography. J Chromatogr 140: 288–292
Dylewicz P, Kirch W, Santos SR, Hutt HJ, Monig H, Ohnhaus EE (1987) Bioavailability and elimination of nitrendipine in liver disease. Eur J Clin Pharmacol 32: 563–568
Humbert H, Denouel J, Keller H (1987) Column liquid chromatographic determination of hydrolysed bopindolol, in the picogram per millilitre — range in plasma using cartridge extraction and dual electrochemical detection. J Chromatogr 422: 205–215
Ohnhaus EE, Nortin J, Kinser J, Colombo JP (1977) Enzyme induction and renal function in man. Br J Clin Pharmacol 4: 33–37
Ohnhaus EE, Park BK (1979) Measurement of urinary 6-β-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme inducing capacity of antipyrine, phenobarbital and rifampicin. Eur J Clin Invest 15: 139–145
Platzer R, Galeazzi RL, Niederberger W, Rosenthaler J (1984) Simultaneous modelling of bopindolol kinetics and dynamics. Clin Pharmacol Ther 36: 5–13
Thompson EN, Williams R (1965) Effect of age upon liver function with particular reference to bromsulphaleine excretion. Gut 6: 266–270
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wensing, G., Branch, R.A., Humbert, H. et al. Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis. Eur J Clin Pharmacol 39, 569–572 (1990). https://doi.org/10.1007/BF00316097
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00316097